Clovis Oncology Inc (fka CLVSQ) (CLVSQ)

[XenaLives]

Rucaparib

Rucaparib, an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2 and 3 is being developed in ovarian cancer as well as several additional solid tumor indications. Studies open for enrollment or under consideration include ovarian, prostate, breast, gastroesophageal, pancreatic, and lung cancers. Clovis holds worldwide rights for rucaparib.

https://clovisoncology.com/pipeline/pipeline-overview/

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 360 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency
Actual Study Start Date : February 15, 2017
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : February 2021

https://www.clinicaltrials.gov/ct2/show/NCT02952534?term=TRITON2&rank=1